Literature DB >> 20233350

Specific amino acid substitutions cause distinct expression of JAL (RH48) and JAHK (RH53) antigens in RhCE and not in RhD.

Pirmin Schmid, Inge von Zabern, Erwin A Scharberg, Franz F Wagner, Willy A Flegel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20233350      PMCID： PMC3482507          DOI： 10.1111/j.1537-2995.2009.02446.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  7 in total

1.  Weak D alleles express distinct phenotypes.

Authors:  F F Wagner; A Frohmajer; B Ladewig; N I Eicher; C B Lonicer; T H Müller; M H Siegel; W A Flegel
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  The RHCE allele ceSL: the second example for D antigen expression without D-specific amino acids.

Authors:  Qing Chen; Hein Hustinx; Willy A Flegel
Journal:  Transfusion       Date:  2006-05       Impact factor: 3.157

3.  Molecular background of VS and weak C expression in blacks.

Authors:  B H Faas; E A Beckers; P Wildoer; P C Ligthart; M A Overbeeke; H A Zondervan; A E von dem Borne; C E van der Schoot
Journal:  Transfusion       Date:  1997-01       Impact factor: 3.157

4.  The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp.

Authors:  Connie M Westhoff; Sunitha Vege; Dwane Wylie; Pam Nickle; Christine Lomas-Francis; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

5.  Molecular basis of the JAHK (RH53) antigen.

Authors:  Erwin A Scharberg; Carole Green; Geoff Daniels; Ekkehard Richter; Harald Klüter; Peter Bugert
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

6.  RhCE protein variants in Southwestern Germany detected by serologic routine testing.

Authors:  Peter Bugert; Erwin A Scharberg; Christof Geisen; Inge von Zabern; Willy A Flegel
Journal:  Transfusion       Date:  2009-05-18       Impact factor: 3.157

7.  Molecular basis of the Rh antigen RH48 (JAL).

Authors:  H Hustinx; J Poole; P Bugert; P Gowland; F Still; S Fontana; E A Scharberg; L Tilley; G Daniels; C Niederhauser
Journal:  Vox Sang       Date:  2008-12-12       Impact factor: 2.144
  7 in total
  3 in total

1.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

2.  Phasing-in RHD genotyping.

Authors:  Willy A Flegel; Susan D Roseff; Ashok Tholpady
Journal:  Arch Pathol Lab Med       Date:  2014-05       Impact factor: 5.534

3.  Molecular and computational analysis of 45 samples with a serologic weak D phenotype detected among 132,479 blood donors in northeast China.

Authors:  Xu Zhang; Guiji Li; Zhuren Zhou; Chaopeng Shao; Xuying Huang; Lichun Li; Xiaofeng Li; Ying Liu; Hua Fan; Jianping Li
Journal:  J Transl Med       Date:  2019-11-27       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.